Juniper Investment Company, LLC (Bartholdson John A., MICHAS ALEXIS P) sold $403K of OFIX (indirect holdings)

Juniper Investment Company, LLC sold 39,500 indirectly-held shares of Orthofix Medical Inc. (OFIX) at an average of $10.20 ($10.01–$10.38, $0.40M total) across 2 trades over 2026-08-14 to 2026-08-17. Filed jointly with Bartholdson John A. (10% owner) and MICHAS ALEXIS P (10% owner).

Original reporting
SEC EDGAR · Juniper Investment Company, LLC, Bartholdson John A., MICHAS ALEXIS P
Published Aug 18, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OFIX
Neutral
medium confidence
Mentioned
$OFIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXNeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale by a 10% owner (indirect holdings) totaling about $402.7K, with no pre-arranged 10b5-1 plan indicated.

02

Market read

Traders may monitor OFIX for sentiment effects from insider selling, but there is no new operational or financial guidance in the text.

03

What to watch

The filing does not state the owner’s rationale, and the transactions occurred over multiple days, reducing the signal of any single timing event.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-18, covering sales dated 2026-08-14 to 2026-08-17

Background

The article is a SEC Form 4 insider transaction disclosure for Orthofix Medical Inc. (OFIX).

Company-level read

Ticker impact

$OFIXNeutralMedium confidence
Context

Orthofix Medical Inc. disclosed a Form 4 showing a 10% owner sold 39,500 shares in open-market transactions at about $10.20.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than a new operating catalyst.

Evidence & confidence

The filing is a primary-source insider transaction, but it does not include earnings, guidance, litigation, or business changes. The sale size is moderate and the article provides no stated reason or plan details beyond 'no pre-arranged 10b5-1 plan.'

Market effects

Minimal sector read-through; this is company-specific insider selling with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

A 10% owner sale can be driven by diversification or liquidity needs and may not reflect negative fundamentals, especially without any accompanying negative company news.

Key entities

  • Orthofix Medical Inc.

    Subject of the Form 4 insider transaction disclosure (OFIX).

  • Juniper Investment Company, LLC

    Reporter of the Form 4, acting as a 10% owner with indirect holdings.

  • Bartholdson John A.

    Co-reporting 10% owner listed on the joint filing.

  • MICHAS ALEXIS P

    Co-reporting 10% owner listed on the joint filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OFIXHighAI 8/10

Orthofix Earnings Call Shows Growth Amid Spine Challenges

Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

Med

Orthofix Medical Inc. Q3 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q3 2026 earnings below expectations due to U.S. Spine market softness and supplier delays. The company is consolidating distributors, with core partners generating 80% of U.S. spinal implant revenue. Updated full-year 2026 revenue guidance is $825M-$830M. Management expects a $22M net sales headwind in 2027 due to European MDR requirements. The VIRATA spinal implant system is set for full market launch in late Q4 2026.

$OFIXMedAI 8/10

Orthofix Medical (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical (OFIX) reported Q3 2026 net sales of $207.9M, up 2.3% YoY. Spine sales fell 1%, while Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively. The company is focusing on strategic partnerships, simplifying its product portfolio, and aligning costs. It expects near-term sales pressure due to these transitions and updated guidance accordingly. Cash reserves stood at $86.9M.

$OFIXMed

Orthofix 3Q 2026: Revenue $207.86M, EPS ($0.15) — 10-Q Summary

Orthofix reported 3Q 2026 revenue of $207.86M, up 1.1% YoY, with a net loss of $6.07M, improved from $22.8M last year. Therapeutic Solutions and Global Limb Reconstruction sales grew, while Spinal Implants and other segments declined. Gross margin fell to 70.5% due to product mix changes. SG&A expenses decreased by $22.8M, driven by lower legal costs and commissions.

$OFIXMed

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Orthofix Medical Inc. (OFIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarte